Untill the FDA trial is underway strange things will happen to the SP . It’s a well calculated plan by whom ever is accumulating . Don’t be surprised if Medtronics or Edwards are behind it . If the SP was to go thu the roof it would enable AVR to do a CR and a FDA listing and it would be possible to fund the entire human trial by selling a relatively small amount of shares . Just remember AVR can raise capital by charging for the TAVR throughout the trial which will cover a portion of the trial costs . I am thinking WP will probably cut some sort of share deal with the majority of the specialists working on the project which in turn could save a substantial amount of trial costs . The last thing the 2 major entities who dominate this field want is AVR to drive this to final approval . Once approved AVR will be worth tens of billions especially considering it comes with the ADAPT IP . IMO there will be substantial offers made sooner rather than latter and by a number of entities whom none of us have even figured into the equation . GLTATH
Add to My Watchlist
What is My Watchlist?
